Allakos (ALLK) Competitors $0.25 -0.01 (-3.88%) Closing price 04:00 PM EasternExtended Trading$0.25 0.00 (-0.40%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALLK vs. BMEA, ARTV, GALT, ATOS, VIRI, PEPG, ANIX, HURA, ADAG, and CLYMShould you be buying Allakos stock or one of its competitors? The main competitors of Allakos include Biomea Fusion (BMEA), Artiva Biotherapeutics (ARTV), Galectin Therapeutics (GALT), Atossa Therapeutics (ATOS), Virios Therapeutics (VIRI), PepGen (PEPG), Anixa Biosciences (ANIX), TuHURA Biosciences (HURA), Adagene (ADAG), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical products" industry. Allakos vs. Biomea Fusion Artiva Biotherapeutics Galectin Therapeutics Atossa Therapeutics Virios Therapeutics PepGen Anixa Biosciences TuHURA Biosciences Adagene Climb Bio Allakos (NASDAQ:ALLK) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends. Do insiders and institutionals hold more shares of ALLK or BMEA? 84.6% of Allakos shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 16.1% of Allakos shares are held by insiders. Comparatively, 27.6% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer ALLK or BMEA? Allakos currently has a consensus price target of $2.00, indicating a potential upside of 700.00%. Biomea Fusion has a consensus price target of $39.36, indicating a potential upside of 1,379.84%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Allakos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allakos 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media refer more to ALLK or BMEA? In the previous week, Allakos had 4 more articles in the media than Biomea Fusion. MarketBeat recorded 5 mentions for Allakos and 1 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.93 beat Allakos' score of 0.48 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Overall Sentiment Allakos Neutral Biomea Fusion Positive Does the MarketBeat Community favor ALLK or BMEA? Allakos received 125 more outperform votes than Biomea Fusion when rated by MarketBeat users. However, 69.05% of users gave Biomea Fusion an outperform vote while only 58.84% of users gave Allakos an outperform vote. CompanyUnderperformOutperformAllakosOutperform Votes18358.84% Underperform Votes12841.16% Biomea FusionOutperform Votes5869.05% Underperform Votes2630.95% Which has more volatility and risk, ALLK or BMEA? Allakos has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Which has better earnings and valuation, ALLK or BMEA? Biomea Fusion is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllakosN/AN/A-$185.70M-$2.03-0.12Biomea FusionN/AN/A-$117.25M-$4.01-0.66 Is ALLK or BMEA more profitable? Biomea Fusion's return on equity of -118.90% beat Allakos' return on equity.Company Net Margins Return on Equity Return on Assets AllakosN/A -140.87% -86.22% Biomea Fusion N/A -118.90%-93.66% SummaryBiomea Fusion beats Allakos on 10 of the 16 factors compared between the two stocks. Remove Ads Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLK vs. The Competition Export to ExcelMetricAllakosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.34M$6.92B$5.61B$7.93BDividend YieldN/A2.72%4.89%4.05%P/E Ratio-0.126.1123.5218.73Price / SalesN/A223.52371.97119.64Price / CashN/A65.6738.0534.64Price / Book0.136.616.844.19Net Income-$185.70M$139.99M$3.19B$246.99M7 Day Performance-1.11%-2.46%5.28%-2.84%1 Month Performance-15.99%-9.02%-1.08%-10.76%1 Year Performance-82.08%-5.12%12.28%0.49% Allakos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLKAllakos4.5029 of 5 stars$0.25-3.9%$2.00+700.0%-80.4%$22.34MN/A-0.12190Short Interest ↓News CoverageGap DownBMEABiomea Fusion2.6634 of 5 stars$2.64-8.7%$39.36+1,391.0%-84.3%$95.67MN/A-0.6650ARTVArtiva BiotherapeuticsN/A$3.92-5.5%$21.00+435.7%N/A$95.21M$2.60M0.0081Gap DownGALTGalectin Therapeutics1.7022 of 5 stars$1.49-5.1%$11.00+638.3%-13.2%$93.52MN/A-2.049Gap DownATOSAtossa Therapeutics1.2663 of 5 stars$0.74-3.2%$7.00+844.7%-45.3%$93.22MN/A-3.378Analyst ForecastVIRIVirios Therapeutics0.4614 of 5 stars$4.79+1.7%$3.00-37.4%+3,444.6%$92.25MN/A-17.745News CoverageGap UpPEPGPepGen2.5386 of 5 stars$2.81-10.8%$10.33+267.7%-82.2%$91.87MN/A-0.9430Short Interest ↑Gap DownANIXAnixa Biosciences2.9293 of 5 stars$2.84-9.8%$8.50+199.3%-13.0%$91.44M$210,000.00-7.285Earnings ReportHURATuHURA BiosciencesN/A$2.16-10.4%$13.00+501.9%N/A$91.34MN/A0.00N/AADAGAdagene2.6438 of 5 stars$2.05+2.0%$8.00+290.2%-33.7%$90.76M$815,746.000.00260Short Interest ↓News CoverageCLYMClimb Bio3.2146 of 5 stars$1.35-6.9%$10.00+640.7%N/A$90.75MN/A-0.639Positive News Remove Ads Related Companies and Tools Related Companies Biomea Fusion Competitors Artiva Biotherapeutics Competitors Galectin Therapeutics Competitors Atossa Therapeutics Competitors Virios Therapeutics Competitors PepGen Competitors Anixa Biosciences Competitors TuHURA Biosciences Competitors Adagene Competitors Climb Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLK) was last updated on 3/13/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allakos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLK Stock Alerts